March 7, 2022 -- Biognosys has launched an expanded suite of proteomics platforms that provide pharmaceutical and diagnostics customers with biological insights across the entire R&D pipeline, from early-stage discovery to clinical settings.
The platforms -- TrueDiscovery, TrueTarget, and TrueSignature -- make it easier for biopharma customers to integrate multiple complementary proteomics solutions across their entire drug discovery and clinical development pipeline, Biognosys said.
Through the TrueSignature platform, Biognosys develops and runs customizable precision proteomics biomarker panels, it said.
TrueDiscovery and TrueTarget build on Biognosys’ existing key offerings for biomarker discovery and drug target identification, respectively, the company said.
Biognosys provides next-generation proteomics solutions for drug discovery and development.
Copyright © 2022 scienceboard.net